Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued ...
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...
Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty ...
7d
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...
Hosted on MSN13d
Biotech Market Forecast: Top Trends for Biotech in 2025The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's ...
In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging” year ...
In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback